Recently, using human iPSC-derived kidney organoids, treatment with TGF-β1 has been shown to induce extracellular matrix production, reflecting pro-fibrotic signaling observed in chronic kidney disease (CKD) [98]. This evidence concerns the gene TGFB1 and chronic kidney disease.